Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.

[1]  W. Kassouf,et al.  Biomarkers for detection and surveillance of bladder cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[2]  P. V. van Diest,et al.  Methylation of the TWIST1 Promoter, TWIST1 mRNA Levels, and Immunohistochemical Expression of TWIST1 in Breast Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[3]  B. Czerniak,et al.  Aberrant Promoter Methylation of Multiple Genes during Pathogenesis of Bladder Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[4]  M. Nakagawa,et al.  Epigenetics in bladder cancer , 2008, International Journal of Clinical Oncology.

[5]  P. Negraes,et al.  DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection , 2008, BMC Cancer.

[6]  V. Lokeshwar,et al.  Bladder tumor markers: from hematuria to molecular diagnostics – where do we stand? , 2008, Expert review of anticancer therapy.

[7]  J. Witjes,et al.  Urinary markers in bladder cancer. , 2008, European urology.

[8]  E. Steyerberg,et al.  Patients’ perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison , 2008, BJU international.

[9]  E. Schuuring,et al.  Genome-wide promoter analysis uncovers portions of the cancer methylome. , 2008, Cancer research.

[10]  L. Budäus,et al.  Methylation of the TPEF‐ and PAX6‐promoters is increased in early bladder cancer and in normal mucosa adjacent to pTa tumours , 2008, BJU international.

[11]  Mihaela Campan,et al.  DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis , 2008, Laboratory Investigation.

[12]  Tongyu Zhu,et al.  A Novel Set of DNA Methylation Markers in Urine Sediments for Sensitive/Specific Detection of Bladder Cancer , 2007, Clinical Cancer Research.

[13]  Wendy Cozen,et al.  Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma , 2007, Molecular Cancer.

[14]  A. Agarwal,et al.  Voided urinary cytology in bladder cancer: is it time to review the indications? , 2007, Urology.

[15]  Paul Cairns,et al.  Gene methylation and early detection of genitourinary cancer: the road ahead , 2007, Nature Reviews Cancer.

[16]  J. Minna,et al.  Methods for detecting DNA methylation in tumors: from bench to bedside. , 2007, Cancer letters.

[17]  Takako Sasaki,et al.  Nidogen 1 and 2 gene promoters are aberrantly methylated in human gastrointestinal cancer , 2007, Molecular Cancer.

[18]  S. Goodman,et al.  Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. , 2006, Journal of the National Cancer Institute.

[19]  S. Baylin,et al.  DNA methylation and gene silencing in cancer , 2005, Nature Clinical Practice Oncology.

[20]  T. Kwast,et al.  Urine markers for bladder cancer surveillance: a systematic review. , 2005 .

[21]  P. Mariappan,et al.  A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. , 2005, The Journal of urology.

[22]  N. Kiviat,et al.  Detection of hypermethylated genes in women with and without cervical neoplasia. , 2005, Journal of the National Cancer Institute.

[23]  J. Herman,et al.  Methylation-Specific PCR Unraveled , 2004, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[24]  M. Justice,et al.  A twist code determines the onset of osteoblast differentiation. , 2004, Developmental cell.

[25]  Manel Esteller,et al.  DNA methylation: a profile of methods and applications. , 2002, BioTechniques.

[26]  Susan J Clark,et al.  DNA methylation and gene silencing in cancer: which is the guilty party? , 2002, Oncogene.

[27]  T. Sasaki,et al.  Nidogen-2: a new basement membrane protein with diverse binding properties. , 1998, Journal of molecular biology.

[28]  K. Loughlin,et al.  Economic impact of tumor markers in bladder cancer surveillance. , 2008, Urology.

[29]  Alberto Redaelli,et al.  The health economics of bladder cancer: a comprehensive review of the published literature. , 2003, PharmacoEconomics.

[30]  E. Olson,et al.  bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. , 1994, Genes & development.